Suppliers and packagers for generic pharmaceutical drug: DECITABINE

DECITABINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Accord Hlthcare	DECITABINE	decitabine	INJECTABLE;INTRAVENOUS	203475	ANDA	Accord Healthcare Inc.	16729-224-05	1 VIAL in 1 CARTON (16729-224-05) / 20 mL in 1 VIAL	2017-03-08
Chemi Spa	DECITABINE	decitabine	INJECTABLE;INTRAVENOUS	206033	ANDA	Amneal Pharmaceuticals LLC	70121-1644-1	1 VIAL, SINGLE-USE in 1 CARTON (70121-1644-1) / 20 mL in 1 VIAL, SINGLE-USE	2019-12-01
Dr Reddys	DECITABINE	decitabine	INJECTABLE;INTRAVENOUS	203131	ANDA	Dr. Reddy's Laboratories Inc.	43598-348-37	1 VIAL, SINGLE-USE in 1 CARTON (43598-348-37) / 10 mL in 1 VIAL, SINGLE-USE	2013-07-11
Dr Reddys	DECITABINE	decitabine	INJECTABLE;INTRAVENOUS	203131	ANDA	Dr. Reddy's Laboratories Inc.	43598-427-37	1 VIAL, SINGLE-USE in 1 CARTON (43598-427-37) / 10 mL in 1 VIAL, SINGLE-USE	2014-12-05
Dr Reddys	DECITABINE	decitabine	INJECTABLE;INTRAVENOUS	203131	ANDA	Dr.Reddy's Laboratories Limited	55111-556-10	1 VIAL, SINGLE-USE in 1 CARTON (55111-556-10) / 10 mL in 1 VIAL, SINGLE-USE	2013-07-11
Eugia Pharma	DECITABINE	decitabine	INJECTABLE;INTRAVENOUS	214569	ANDA	Eugia US LLC	55150-376-01	1 VIAL, SINGLE-DOSE in 1 CARTON (55150-376-01) / 26 mL in 1 VIAL, SINGLE-DOSE	2021-09-20

DECITABINE API SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the suppliers of Decitabine active pharmaceutical ingredient (API), focusing on manufacturers with current regulatory filings and market presence. The analysis includes key geographical locations, capacity indicators, and potential risks within the supply chain.

Who Are the Primary Manufacturers of Decitabine API?

The manufacturing landscape for Decitabine API is concentrated among a limited number of companies with established Good Manufacturing Practices (GMP) compliance and documented production capabilities. These manufacturers are critical for ensuring the availability of this antineoplastic agent used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

The primary suppliers identified through regulatory filings and industry databases include:

• Adcock Ingram
  • This South African pharmaceutical company is a significant player in the Decitabine API market.
  • They operate manufacturing facilities compliant with international regulatory standards.
  • Their involvement ensures a supply channel accessible to various global markets.
• Teva Pharmaceutical Industries Ltd.
  • Teva, a global pharmaceutical giant, is a known producer of Decitabine API.
  • With extensive manufacturing infrastructure and a broad regulatory footprint, Teva contributes to the stability of the Decitabine supply.
  • Their diversified operations can mitigate some supply chain risks.
• Mylan N.V. (now part of Viatris)
  • Prior to its merger with Pfizer's Upjohn business to form Viatris, Mylan was a recognized supplier of Decitabine API.
  • The integrated entity, Viatris, likely continues these manufacturing operations, maintaining supply capabilities.
  • Viatris possesses a global network of manufacturing sites.
• Accord Healthcare Limited
  • Accord Healthcare, a subsidiary of Intas Pharmaceuticals, is a supplier of Decitabine API.
  • The company has a growing presence in generic pharmaceuticals and API manufacturing.
  • Their manufacturing sites are designed to meet stringent quality and regulatory requirements.
• Fresenius Kabi AG
  • Fresenius Kabi, a German healthcare company, manufactures and supplies Decitabine API.
  • Their focus on critical care products, including oncology, positions them as a key provider.
  • The company has a robust quality management system and regulatory adherence.

These entities represent the core of the current commercial Decitabine API supply. Their production capacity, regulatory approvals, and geographical diversification are key factors for market stability.

What Are the Key Geographical Hubs for Decitabine API Production?

The production of Decitabine API is geographically dispersed, with significant manufacturing presence in established pharmaceutical regions. This distribution offers some resilience against regional disruptions but also highlights potential geopolitical and logistical dependencies.

Key geographical hubs include:

• India:
  • India is a prominent global hub for API manufacturing, including complex molecules like Decitabine.
  • Numerous Indian pharmaceutical companies operate GMP-certified facilities, benefiting from cost-effectiveness and a skilled workforce.
  • While specific Decitabine API manufacturers in India might not always have direct public filings, many serve as indirect suppliers or contract manufacturers for global pharmaceutical firms.
• Europe:
  • European countries, particularly Germany and Ireland, host manufacturing sites for major pharmaceutical companies involved in Decitabine API production.
  • These facilities adhere to stringent European Medicines Agency (EMA) regulations and are known for high-quality standards.
  • Companies like Fresenius Kabi operate significant manufacturing bases in Europe.
• North America:
  • While less dominant in direct API manufacturing compared to India or Europe, North America plays a role in the pharmaceutical supply chain.
  • Some companies may have specialized manufacturing capabilities or conduct final API purification and formulation within the region.
  • Regulatory oversight from the U.S. Food and Drug Administration (FDA) is paramount for any API supplied to the U.S. market.
• South Africa:
  • Adcock Ingram's operations in South Africa establish this region as a notable supplier, particularly for markets with established relationships with African pharmaceutical producers.
  • This presence diversifies the geographical footprint of Decitabine API manufacturing.

The concentration of manufacturing in these regions means that geopolitical events, trade policies, and localized regulatory changes in these areas can have a direct impact on global Decitabine API availability.

What are the Regulatory and Quality Considerations for Decitabine API Suppliers?

Suppliers of Decitabine API must adhere to rigorous regulatory standards and maintain exceptionally high-quality control measures to ensure product safety and efficacy. These requirements are non-negotiable for pharmaceutical use.

Key regulatory and quality considerations include:

• Good Manufacturing Practices (GMP):
  • All manufacturers must comply with current Good Manufacturing Practices (cGMP) as defined by major regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities.
  • Compliance includes stringent controls over raw materials, manufacturing processes, facility maintenance, personnel training, and quality assurance.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs):
  • API manufacturers typically file DMFs (in the U.S.) or ASMFs (in Europe) with regulatory agencies. These confidential documents detail the manufacturing process, quality control procedures, and facility information.
  • Pharmaceutical companies seeking to use the API in their drug products reference these filings in their marketing authorization applications.
  • The completeness and accuracy of DMFs/ASMFs are critical for regulatory approval.
• Impurity Profiling and Control:
  • Decitabine, as a cytotoxic agent, requires meticulous control over impurities, including related substances, residual solvents, and potential genotoxic impurities.
  • Suppliers must have validated analytical methods to detect and quantify all relevant impurities at very low levels.
  • ICH (International Council for Harmonisation) guidelines provide frameworks for impurity control.
• Stability Studies:
  • Manufacturers must conduct comprehensive stability studies to determine the shelf life of the API under various storage conditions.
  • These studies ensure the API remains within specified quality limits throughout its intended storage period.
• Supply Chain Security and Traceability:
  • Robust systems for tracking raw materials, intermediates, and the finished API are essential.
  • This ensures the integrity of the supply chain and facilitates recalls if necessary.
• Site Inspections and Audits:
  • Regulatory agencies conduct periodic inspections of manufacturing facilities to verify GMP compliance.
  • Pharmaceutical companies also conduct their own audits of API suppliers as part of their vendor qualification process.

Failure to meet these standards can result in regulatory sanctions, product recalls, and significant business disruption for both API suppliers and their pharmaceutical customers.

What are the Potential Risks and Mitigations in the Decitabine API Supply Chain?

The supply chain for Decitabine API, like any specialized pharmaceutical ingredient, faces several inherent risks. Proactive identification and mitigation strategies are crucial for ensuring uninterrupted access to this vital medication.

Key Risks:

• Single-Sourcing Dependency:
  • Reliance on a single manufacturer for Decitabine API creates significant vulnerability. Any disruption at that supplier's facility, whether due to production issues, regulatory non-compliance, or geopolitical instability, could halt supply.
  • Mitigation: Diversify the supplier base. Qualify and establish relationships with at least two or three alternative GMP-certified API manufacturers. Maintain adequate safety stock levels.
• Regulatory Non-Compliance:
  • A supplier failing a regulatory inspection or having a DMF/ASMF withdrawn can immediately impact supply. This is a constant risk due to evolving regulatory standards and the complexity of pharmaceutical manufacturing.
  • Mitigation: Conduct rigorous due diligence and ongoing quality audits of all suppliers. Monitor regulatory agency warning letters and enforcement actions relevant to potential suppliers.
• Geopolitical and Trade Disruptions:
  • Political instability, trade wars, tariffs, or export restrictions in key manufacturing regions (e.g., India, China) can disrupt the flow of APIs.
  • Mitigation: Map the supply chain geographically and assess geopolitical risks in each region. Consider suppliers located in politically stable regions or diversify manufacturing locations.
• Raw Material Shortages and Price Volatility:
  • The synthesis of Decitabine involves specific precursor chemicals. Shortages or price hikes in these raw materials can impact the cost and availability of the final API.
  • Mitigation: Understand the upstream supply chain for critical raw materials. Establish strong relationships with multiple raw material suppliers and explore alternative synthesis routes if feasible.
• Logistical Challenges:
  • Transportation disruptions (e.g., shipping delays, port congestion, air cargo limitations) can impede the timely delivery of APIs. Specialized handling requirements for certain APIs can exacerbate these challenges.
  • Mitigation: Work with experienced pharmaceutical logistics providers. Develop contingency plans for transportation and explore different shipping modes or routes.
• Intellectual Property (IP) Disputes:
  • While Decitabine is an older drug, disputes over manufacturing processes or intermediate compounds could potentially arise, leading to injunctions.
  • Mitigation: Ensure that suppliers have clear title to their manufacturing processes and are not infringing on any existing patents. Conduct IP landscape reviews.
• Quality Control Failures:
  • Batch failures due to manufacturing errors or contamination can lead to significant delays, product rejections, and reputational damage.
  • Mitigation: Implement robust quality agreements with suppliers. Conduct thorough incoming material testing and regular batch reviews.

Strategic Mitigation:

A proactive approach involves creating a resilient supply chain architecture. This includes:

1. Supplier Qualification and Auditing Program: A comprehensive program that goes beyond initial qualification to include regular, risk-based audits.
2. Dual/Multi-Sourcing Strategy: Actively working to have at least two qualified suppliers for critical APIs.
3. Geographical Diversification: Seeking suppliers in different geographical regions to avoid concentration risk.
4. Inventory Management: Balancing the costs of holding inventory against the risks of stock-outs. This includes strategic safety stock levels.
5. Contractual Safeguards: Ensuring supply agreements include provisions for quality, delivery timelines, business continuity, and change control.
6. Regulatory Intelligence: Continuously monitoring regulatory changes and enforcement actions affecting API manufacturing.
7. Technology Adoption: Exploring advanced analytics for supply chain visibility and risk prediction.

What is the Current Market Status and Future Outlook for Decitabine API?

The market for Decitabine API is primarily driven by its established therapeutic applications in hematological malignancies. The outlook is influenced by factors such as patent expiries of branded formulations, the growth of generic competition, and the development of new treatment modalities.

Current Market Status:

• Established Therapeutic Use: Decitabine is a well-recognized treatment option for Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML), particularly for patients who may not be candidates for intensive chemotherapy.
• Generic Penetration: With the expiry of key patents for the originator drug (e.g., Dacogen by Otsuka Pharmaceutical), the market has seen significant generic competition. This has led to increased demand for Decitabine API from generic manufacturers.
• Pricing Pressures: The entry of multiple generic suppliers has intensified price competition, driving down the cost of finished drug products and, consequently, placing downward pressure on API pricing.
• Regulatory Approvals: The availability of generic Decitabine products is contingent on regulatory approvals in various markets, requiring API suppliers to meet stringent quality and dossier requirements.
• Supply Chain Resilience: While genericization increases API demand, the market remains susceptible to supply chain disruptions due to the specialized nature of its production and the limited number of primary manufacturers.

Future Outlook:

• Sustained Demand for Generics: The demand for generic Decitabine is expected to remain steady, driven by its continued use in standard treatment protocols for MDS and AML. As global access to healthcare expands, particularly in emerging markets, the demand for affordable generic options will likely increase.
• Potential for New Formulations or Combinations: Research into novel drug delivery systems or combination therapies involving Decitabine could emerge. While this might require new API specifications, it could also open avenues for API suppliers to adapt their offerings.
• Consolidation Among API Manufacturers: The API manufacturing sector, especially for established generics, is subject to consolidation. This could lead to fewer but larger players in the Decitabine API market, potentially impacting pricing and supply dynamics.
• Increased Regulatory Scrutiny: Regulatory bodies are continuously enhancing their oversight of API quality and supply chain integrity. Suppliers will need to invest in maintaining and upgrading their GMP compliance and data management systems.
• Geopolitical Influence: Global trade policies, supply chain nationalism, and regional manufacturing incentives will continue to play a significant role in where API production is concentrated and how it is distributed.
• Emergence of New Competitors: While the current landscape is defined by established players, the generic API market is dynamic. New entrants, particularly from regions with competitive manufacturing capabilities, could emerge if market conditions and regulatory pathways are favorable.

The future of the Decitabine API market is characterized by a balance between the growing demand for generic treatments and the imperative for robust, high-quality, and secure supply chains. Manufacturers and pharmaceutical companies must remain vigilant regarding regulatory compliance, supply chain risks, and evolving market dynamics.

Key Takeaways

• Decitabine API manufacturing is concentrated among a select group of global pharmaceutical companies, including Adcock Ingram, Teva, Viatris (formerly Mylan), Accord Healthcare, and Fresenius Kabi.
• Key geographical production hubs are India, Europe, North America, and South Africa, each with distinct regulatory and operational characteristics.
• Adherence to cGMP, comprehensive impurity control, and robust quality management systems are paramount for Decitabine API suppliers.
• Significant risks to the supply chain include single-sourcing dependency, regulatory non-compliance, geopolitical disruptions, raw material shortages, and logistical challenges.
• Mitigation strategies must involve dual/multi-sourcing, geographical diversification, rigorous auditing, strategic inventory management, and strong contractual safeguards.
• The market for Decitabine API is driven by generic competition for established indications, leading to pricing pressures but sustained demand. Future growth will depend on generic market expansion, potential new formulations, and ongoing regulatory and geopolitical influences.

Frequently Asked Questions

1. What is the typical lead time for procuring Decitabine API from a qualified supplier? Lead times can vary significantly based on the supplier's current production schedule, order volume, and existing inventory. Generally, for established GMP-compliant suppliers with active DMFs, lead times for bulk API orders can range from 3 to 6 months. However, expedited orders may be possible at a premium or if the supplier has available stock.

2. How do FDA inspections of Decitabine API manufacturing sites affect supply? FDA inspections are critical. A successful inspection confirms GMP compliance. Conversely, a "Form 483" observation list or a Warning Letter indicates deficiencies that could lead to production halts, import alerts, or the need for extensive remediation. Such events can directly disrupt the supply of Decitabine API to the U.S. market and potentially impact global supply if the facility is a primary producer.

3. Are there any specific requirements for the packaging and shipping of Decitabine API? Yes. Decitabine API is a cytotoxic agent and requires specialized handling and packaging to prevent contamination and ensure personnel safety. Packaging typically involves robust, sealed containers, often with secondary containment, designed to maintain product integrity and prevent leakage during transport. Shipping must comply with regulations for the transport of hazardous materials, including proper labeling, documentation, and temperature control if required by stability data.

4. What is the difference between an API supplier's DMF and an ASMF? A Drug Master File (DMF) is submitted to the U.S. Food and Drug Administration (FDA) and contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. An Active Substance Master File (ASMF) serves a similar purpose but is submitted to the European Medicines Agency (EMA) and other European regulatory authorities. Both are used by regulatory agencies to review the API as part of a drug product application.

5. Can a pharmaceutical company that manufactures its own Decitabine API still be considered at risk in the supply chain? Yes, even in-house manufacturing carries risks. Internal production sites are subject to the same regulatory scrutiny (e.g., FDA inspections) and operational risks (e.g., equipment failure, contamination, raw material sourcing issues) as external suppliers. Companies with internal API manufacturing often still maintain relationships with external suppliers to ensure supply continuity, manage capacity constraints, or hedge against specific internal production vulnerabilities.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files-dmfs [2] European Medicines Agency. (n.d.). Active Substance Master Files (ASMFs). Retrieved from [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ Guideline-active-substance-master-file-procedure_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ Guideline-active-substance-master-file-procedure_en.pdf) [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guideline Impurities: Guideline for Residual Solvents Q3C(R6). Retrieved from https://www.ich.org/page/quality-guidelines [4] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/good-manufacturing-practice-gmp-regulations